58,413 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Bought by Trek Financial LLC

Trek Financial LLC acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 58,413 shares of the company's stock, valued at approximately $2,825,000. Trek Financial LLC owned about 0.10% of Protagonist Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership raised its holdings in Protagonist Therapeutics by 36.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company's stock valued at $8,340,000 after buying an additional 58,002 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Protagonist Therapeutics by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company's stock valued at $22,327,000 after buying an additional 12,906 shares during the last quarter. GAMMA Investing LLC raised its holdings in Protagonist Therapeutics by 12,147.8% during the 1st quarter. GAMMA Investing LLC now owns 58,177 shares of the company's stock valued at $2,813,000 after buying an additional 57,702 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Protagonist Therapeutics by 84.1% during the 4th quarter. Victory Capital Management Inc. now owns 240,817 shares of the company's stock valued at $9,296,000 after buying an additional 110,020 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in Protagonist Therapeutics by 18.7% during the 4th quarter. Teacher Retirement System of Texas now owns 13,099 shares of the company's stock valued at $506,000 after buying an additional 2,067 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Citigroup assumed coverage on shares of Protagonist Therapeutics in a report on Tuesday, June 17th. They set a "buy" rating and a $72.00 price target for the company. Wall Street Zen upgraded shares of Protagonist Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, June 8th. Truist Financial lifted their price target on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a research report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Finally, Wedbush restated an "outperform" rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, March 28th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $66.10.

Insider Activity at Protagonist Therapeutics

In related news, CFO Asif Ali sold 1,756 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total transaction of $80,776.00. Following the completion of the sale, the chief financial officer directly owned 61,065 shares in the company, valued at approximately $2,808,990. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Arturo Md Molina sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $57.03, for a total transaction of $570,300.00. Following the sale, the insider owned 83,892 shares of the company's stock, valued at $4,784,360.76. This trade represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.90% of the company's stock.

Protagonist Therapeutics Stock Performance

Shares of PTGX stock traded down $0.17 during trading hours on Tuesday, reaching $49.70. The company had a trading volume of 591,635 shares, compared to its average volume of 842,646. The business has a fifty day moving average price of $49.51 and a 200-day moving average price of $44.75. Protagonist Therapeutics, Inc. has a one year low of $32.50 and a one year high of $60.60. The firm has a market cap of $3.08 billion, a PE ratio of 66.27 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.31. The company had revenue of $28.32 million during the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a net margin of 27.04% and a return on equity of 9.22%. Equities research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.